Fertility-sparing management of endometrial adenocarcinoma

Obstetrical and Gynecological Survey

Volumn 66, Issue 7, 2011, Pages 443-451

  Dorais, Jessie ^a   Dodson, Mark ^b   Calvert, Jacob ^a   Mize, Benjamin ^a   Travarelli, Jennifer Mitchell ^a   Jasperson, Kory ^b   Peterson, Charles Matthew ^a   Soisson, Andrew P ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ESTROGEN RECEPTOR; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MISMATCH REPAIR PROTEIN PMS2; NORETHISTERONE; PROGESTERONE RECEPTOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

BREAST TENDERNESS; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CRYOPRESERVATION; DIAGNOSTIC ACCURACY; DILATION AND EVACUATION; DISEASE FREE SURVIVAL; DRUG INDUCED HEADACHE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE FERTILITY; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYSTERECTOMY; LIBIDO; METASTASIS; MOOD CHANGE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVARY CANCER; PREGNANCY; PREMENOPAUSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; THROMBOPHLEBITIS; TRANSVAGINAL ECHOGRAPHY; TREATMENT RESPONSE; WEIGHT GAIN;

ADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; PREMENOPAUSE; RISK FACTORS;

EID: 80053324700     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31822f8f66     Document Type: Review

References (102)

1. Duska LR, Garrett A, Rueda BR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83: 388-393. (Pubitemid 33033084)
2. Evans-Metcalf ER, Brooks SE, Reale FR, et al. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998;91:349-354. (Pubitemid 28119833)
3. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417-420. (Pubitemid 14073467)
4. Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655-662. (Pubitemid 46339405)
5. Hill HA, Austin H. Nutrition and endometrial cancer. Cancer Causes Control. 1996;7:19-32. (Pubitemid 26065007)
6. Tornberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer. 1994;69: 358-361. (Pubitemid 24046563)
7. La Vecchia C, Parazzini F, Negri E, et al. Anthropometric indicators of endometrial cancer risk. Eur J Cancer. 1991;27: 487-490.
8. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72:263-271.
9. Dijkhuizen FP, Mol BW, Brolmann HA, et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765-1772.
10. Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol. 2009;114:523-529.
11. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133-138. (Pubitemid 39286288)
12. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol. 2004;117:132-137. (Pubitemid 39487319)
13. Rackow BW, Arici A. Endometrial cancer and fertility. Curr Opin Obstet Gynecol. 2006;18:245-252. (Pubitemid 43864722)
14. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22:1953-1958. (Pubitemid 47062765)
15. Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol. 1988;158(3 Pt 1):489-492. (Pubitemid 18088190)
16. Symonds I. Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001;15:381-391. (Pubitemid 32631471)
17. Biewenga P, de Blok S, Birnie E. Does diagnostic hysteroscopy in patients with stage I endometrial carcinoma cause positive peritoneal washings? Gynecol Oncol. 2004;93:194-198. (Pubitemid 38429570)
18. Revel A, Tsafrir A, Anteby SO, et al. Does hysteroscopy produce intraperitoneal spread of endometrial cancer cells? Obstet Gynecol Surv. 2004;59:280-284. (Pubitemid 38393219)
19. Selvaggi L, Cormio G, Ceci O, et al. Hysteroscopy does not increase the risk of microscopic extrauterine spread in endometrial carcinoma. Int J Gynecol Cancer. 2003;13:223-227. (Pubitemid 37055482)
20. Takac I, Zegura B. Office hysteroscopy and the risk of microscopic extrauterine spread in endometrial cancer. Gynecol Oncol. 2007;107:94-98. (Pubitemid 47464549)
21. Barwick TD, Rockall AG, Barton DP, et al. Imaging of endometrial adenocarcinoma. Clin Radiol. 2006;61:545-555. (Pubitemid 43899341)
22. Mazzon I, Corrado G, Masciullo V, et al. Conservative surgi-cal management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286-1289.
23. Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009;19:1529-1536.
24. Gitsch G, Hanzal E, Jensen D, et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. 1995;85:504-508.
25. Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693-699. (Pubitemid 41362170)
26. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. Am J Roentgenol. 2010;194:311-321.
27. Shaaban A, Rezvani M. Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol. 2009;52:73-93.
28. Yoon JH, Yoo SC, Kim WY, et al. Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus. Ann Surg Oncol. 2010;17:3234-3240.
29. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005;50:585-590. (Pubitemid 41193137)
30. Han SS, Lee SH, Kim DH, et al. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstet Gynecol Scand. 2010;89:168-174.
31. Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501-1505.
32. Ebina Y, Sakuragi N, Hareyama H, et al. Para-aortic lymph node metastasis in relation to serum CA 125 levels and nuclear grade in endometrial carcinoma. Acta Obstet Gynecol Scand. 2002;81:458-465. (Pubitemid 34526342)
33. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(suppl 8):2035-2041. (Pubitemid 17145924)
34. Fernandez-Montoli BE, Miralpeix G, Gine-Martinez L. Conservative treatments in gynaecological cancer for fertility preservation [Intervention Protocol]. Cochrane Database Syst Rev. 2010:1-12.
35. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744. (Pubitemid 29269242)
36. Ingram SS, Rosenman J, Heath R, et al. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys. 1989;17:21-27. (Pubitemid 19173234)
37. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106:812-819. (Pubitemid 43238448)
38. Pennant S, Manek S, Kehoe S. Endometrial atypical hyperplasia and subsequent diagnosis of endometrial cancer: a retrospective audit and literature review. J Obstet Gynaecol. 2008;28:632-633.
39. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol. 1994;52:373-378. (Pubitemid 24125555)
40. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 15 1982;49:2547-2559. (Pubitemid 12125049)
41. Valenzuela P, Sanz JM, Keller J. Atypical endometrial hyperplasia: grounds for possible misdiagnosis of endometrial adenocarcinoma. Gynecol Obstet Invest. 2003;56:163-167. (Pubitemid 37346765)
42. Shutter J, Wright TC Jr. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol. 2005;24:313-318. (Pubitemid 41368281)
43. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106:804-811. (Pubitemid 43238447)
44. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66: 7810-7817. (Pubitemid 44289242)
45. Hampel H, Panescu J, Lockman J, et al. Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2007;67:9603. (Pubitemid 47535953)
46. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25: 5158-5164. (Pubitemid 350232246)
47. Walsh CS, Blum A, Walts A, et al. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol. 2010;116:516-521.
48. Kwon JS, Sun CC, Peterson SK, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008;113:326-335.
49. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268. (Pubitemid 38256271)
50. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010;8:8-61.
51. Mvundura M, Grosse SD, Hampel H, et al. The costeffectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93-104.
52. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130:665-671. (Pubitemid 43374516)
53. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutationnegative family members. J Clin Oncol. 2009;27:4793-4797.
54. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55-65.
55. Vinker S, Shani A, Open M, et al. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate? Eur J Obstet Gynecol Reprod Biol. 1999; 83:63-65. (Pubitemid 29101575)
56. Yasuda M, Matsui N, Kajiwara H, et al. Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathol Int. 2004;54:451-456. (Pubitemid 38829933)
57. Ferrandina G, Zannoni GF, Gallotta V, et al. Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol. 2005;99:215-217. (Pubitemid 41354604)
58. Ota T, Yoshida M, Kimura M, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005;15:657-662. (Pubitemid 41022904)
59. Cormio G, Martino R, Loizzi V, et al. A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer. 2006;16:2044-2048. (Pubitemid 44924369)
60. Chiva de Agustin L, Lapuente Sastre F, Corraliza Galan V, et al. Conservative management of patients with early endometrial carcinoma: a systematic review. Clin Transl Oncol. 2008; 10:155-162.
61. Tangjitgamol S, Manusirivithaya S, Hanprasertpong J. Fertilitysparing in endometrial cancer. Gynecol Obstet Invest. 2009;67: 250-268.
62. Ovarian tissue and oocyte cryopreservation. Fertil Steril. 2008;90(suppl 5):S241-S246.
63. Liou WS, Yap OW, Chan JK, et al. Innovations in fertility preservation for patients with gynecologic cancers. Fertil Steril. 2005;84:1561-1573. (Pubitemid 41785643)
64. Lowe MP, Cooper BC, Sood AK, et al. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol. 2003;91:569-572. (Pubitemid 38388152)
65. Burnett AF, Bahador A, Amezcua C. Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol. 2004;94:832-834. (Pubitemid 39194485)
66. Cade TJ, Quinn MA, Rome RM, et al. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117:879-884.
67. Chang WH, Chen CH, Yu MH. Conservative therapy of stage I endometrial adenocarcinoma and atypical endometrial hyperplasia for the preservation of fertility. Int J Gynaecol Obstet. 2006;92:137-138.
68. Dhar KK, NeedhiRajan T, Koslowski M, et al. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97:924-927. (Pubitemid 40824667)
69. Eftekhar Z, Izadi-Mood N, Yarandi F, et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009;19:249-252.
70. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertilitysparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102:718-725. (Pubitemid 37206407)
71. Gurgan T, Bozdag G, Demirol A, et al. Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review. Reprod Biomed Online. 2007;15:561-565. (Pubitemid 350167079)
72. Huang SY, Jung SM, Ng KK, et al. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol. 2005;97: 652-655.
73. Hurst SA, Hartzfeld KM, Del Priore G. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer. Fertil Steril. 2008; 89:724 e721-723.
74. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79:320-327. (Pubitemid 27029896)
75. Kung FT, Chen WJ, Chou HH, et al. Conservative management of early endometrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod. 1997;12:1649-1653.
76. Lowe MP, Bender D, Sood AK, et al. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril. 2002;77:188-189. (Pubitemid 34093917)
77. Mao Y, Wan X, Chen Y, et al. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril. 2010;93:283-285.
78. Niwa K, Tagami K, Lian Z, et al. Outcome of fertilitypreserving treatment in young women with endometrial carcinomas. BJOG. 2005;112:317-320. (Pubitemid 40314007)
79. Ogawa S, Koike T, Shibahara H, et al. Assisted reproductive technologies in conjunction with conservatively treated endometrial adenocarcinoma. A case report. Gynecol Obstet Invest. 2001;51:214-216. (Pubitemid 32304748)
80. Park JC, Cho CH, Rhee JH. A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer. J Korean Med Sci. 2006; 21:567-571.
81. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90: 434-440. (Pubitemid 27357938)
82. Sardi J, Anchezar Henry JP, Paniceres G, et al. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Oncol. 1998;19:565-568. (Pubitemid 29008299)
83. Sodano M, Bogliatto F, Morero S, et al. Case report: successful IVF programme after conservatively treated endometrial cancer. Reprod Biomed Online. 2009;18:578-581.
84. Sparac V, Ujevic B, Ujevic M, et al. Successful pregnancy after hysteroscopic removal of grade I endometrial carcinoma in a young woman with Lynch syndrome. Int J Gynecol Cancer. 2006;16(suppl 1):442-445.
85. Takahashi N, Hirashima Y, Harashima S, et al. A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy. Arch Gynecol Obstet. 2008;278:365-367.
86. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798-2803. (Pubitemid 47123189)
87. Wang CB, Wang CJ, Huang HJ, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94:2192-2198.
88. Yahata T, Fujita K, Aoki Y, et al. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006;21:1070-1075.
89. Yang YC, Wu CC, Chen CP, et al. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol. 2005;99:287-293.
90. Yasuda M, Terai Y, Sekijima T, et al. Successful pregnancy after conservative surgery for stage IA endometrial cancer in a young woman. Fertil Steril. 2009;91:936 e913-e935.
91. Yu M, Yang JX, Wu M, et al. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril. 2009;92:2122-2124.
92. Elizur SE, Beiner ME, Korach J, et al. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007; 88:1562-1567. (Pubitemid 350225705)
93. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril. 2003;80:1315-1324. (Pubitemid 37532439)
94. Toner JP, Grainger DA, Frazier LM. Clinical outcomes among recipients of donated eggs: an analysis of the US national experience, 1996-1998. Fertil Steril. 2002;78:1038-1045. (Pubitemid 35292506)
95. Zivanovic O, Carter J, Kauff ND, et al. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol. 2009;115:504-509.
96. Pinto AB, Gopal M, Herzog TJ, et al. Successful in vitro fertilization pregnancy after conservative management of endometrial cancer. Fertil Steril. 2001;76:826-829. (Pubitemid 32928414)
97. Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer: how many could be eligible for fertilitysparing treatment? Gynecol Oncol. 2009;114:448-451.
98. Juretzka MM, O'Hanlan KA, Katz SL, et al. Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril. 2005;83:1041.
99. Yarali H, Bozdag G, Aksu T, et al. A successful pregnancy after intracytoplasmic sperm injection and embryo transfer in a patient with endometrial cancer who was treated conservatively. Fertil Steril. 2004;81:214-216. (Pubitemid 38058353)
100. Hernandez E. ACOG Practice Bulletin number 65: management of endometrial cancer. Obstet Gynecol. 2006;107:952; author reply 952-953.
101. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol. 2008;111:231-241.
102. Michaelson-Cohen R, Beller U. Managing menopausal symptoms after gynecological cancer. Curr Opin Oncol. 2009;21:407-411.